应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SPRY ARS PHARMACEUTICALS INC
盘前交易 01-22 08:34:43 EST
10.44
-0.01
-0.10%
盘前
10.74
+0.30
+2.87%
08:02 EST
最高
10.50
最低
10.02
成交量
158.42万
今开
10.25
昨收
10.45
日振幅
4.59%
总市值
10.32亿
流通市值
5.77亿
总股本
9,885万
成交额
1,629万
换手率
2.87%
流通股本
5,527万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.24%
市场透视 · 01-12
Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.24%
ARS Pharmaceuticals将获400万美元监管里程碑付款,并有望获得高达8000万美元销售里程碑
美股速递 · 2025-12-29
ARS Pharmaceuticals将获400万美元监管里程碑付款,并有望获得高达8000万美元销售里程碑
Neffy®(肾上腺素鼻喷雾剂)在华获批,成为首个且唯一可用于社区治疗的过敏反应(严重过敏)急救产品
美股速递 · 2025-12-29
Neffy®(肾上腺素鼻喷雾剂)在华获批,成为首个且唯一可用于社区治疗的过敏反应(严重过敏)急救产品
异动解读 | ARS制药季度业绩亮眼,股价盘前飙升7.34%
异动解读 · 2025-11-10
异动解读 | ARS制药季度业绩亮眼,股价盘前飙升7.34%
ARS Pharmaceuticals公布2025年第三季度财务结果及Neffy®的亮点
美股速递 · 2025-11-10
ARS Pharmaceuticals公布2025年第三季度财务结果及Neffy®的亮点
Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.05%
市场透视 · 2025-11-06
Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.05%
ARS Pharma推出GET Neffy®以改善重度过敏反应患者对Neffy(肾上腺素鼻喷雾剂)的获取
美股速递 · 2025-11-04
ARS Pharma推出GET Neffy®以改善重度过敏反应患者对Neffy(肾上腺素鼻喷雾剂)的获取
Ars Pharmaceuticals, Inc.盘中异动 临近收盘快速下跌5.08%报9.16美元
市场透视 · 2025-10-25
Ars Pharmaceuticals, Inc.盘中异动 临近收盘快速下跌5.08%报9.16美元
Ars Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.01%
市场透视 · 2025-10-10
Ars Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.01%
ARS Pharmaceuticals就Neffy®(肾上腺素鼻喷剂)相关专利获得欧洲专利局有利决定
美股速递 · 2025-10-08
ARS Pharmaceuticals就Neffy®(肾上腺素鼻喷剂)相关专利获得欧洲专利局有利决定
Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.45%报10.25美元
市场透视 · 2025-09-30
Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.45%报10.25美元
ARS Pharmaceuticals获得高达2.5亿美元贷款额度,与Ra Capital Management和Omers Life Sciences合作加速Neffy®在美国的商业化
美股速递 · 2025-09-30
ARS Pharmaceuticals获得高达2.5亿美元贷款额度,与Ra Capital Management和Omers Life Sciences合作加速Neffy®在美国的商业化
Neffy®(肾上腺素鼻喷剂)在日本获批,成为首个且唯一的无针头过敏反应(过敏性休克)紧急治疗药物
美股速递 · 2025-09-19
Neffy®(肾上腺素鼻喷剂)在日本获批,成为首个且唯一的无针头过敏反应(过敏性休克)紧急治疗药物
Ars Pharmaceuticals, Inc.盘中异动 临近收盘急速下挫5.02%
市场透视 · 2025-09-17
Ars Pharmaceuticals, Inc.盘中异动 临近收盘急速下挫5.02%
异动解读 | ARS制药业绩报告后股价盘中大跌5.46%,尽管收入超预期但亏损仍然严重
异动解读 · 2025-08-13
异动解读 | ARS制药业绩报告后股价盘中大跌5.46%,尽管收入超预期但亏损仍然严重
Ars Pharmaceuticals, Inc.盘中异动 早盘快速下跌5.00%报16.63美元
市场透视 · 2025-08-11
Ars Pharmaceuticals, Inc.盘中异动 早盘快速下跌5.00%报16.63美元
ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖,给予跑赢大盘评级, 目标价30.00美元。
金融界 · 2025-03-08
ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖,给予跑赢大盘评级, 目标价30.00美元。
Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.01%报10.69美元
市场透视 · 2025-03-05
Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.01%报10.69美元
Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.57%报10.80美元
市场透视 · 2025-02-27
Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.57%报10.80美元
Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.16%报10.66美元
市场透视 · 2025-02-24
Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.16%报10.66美元
加载更多
公司概况
公司名称:
ARS PHARMACEUTICALS INC
所属市场:
NASDAQ
上市日期:
--
主营业务:
ARS Pharmaceuticals, Inc.于2016年1月4日根据特拉华州法律成立。该公司是一家生物制药公司,专注于开发新型、可能是一流的候选产品,neffy用于I型过敏反应的紧急治疗,包括过敏反应。neffy是一种肾上腺素的专有组合物,具有一种名为Intravail的创新吸收增强剂,允许neffy以小剂量、易于携带、易于使用、快速给药和可靠的鼻喷雾剂提供注射般的肾上腺素吸收。
发行价格:
--
{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":10.44,"timestamp":1769029200000,"preClose":10.45,"halted":0,"volume":1584188,"hourTrading":{"tag":"盘前","latestPrice":10.74,"preClose":10.44,"latestTime":"08:02 EST","volume":4,"amount":42.96,"timestamp":1769086976104,"change":0.3,"changeRate":0.028736,"amplitude":0},"delay":0,"changeRate":-0.0009569377990430418,"floatShares":55270496,"shares":98848611,"eps":-0.81541,"marketStatus":"盘前交易","change":-0.01,"latestTime":"01-22 08:34:43 EST","open":10.25,"high":10.5,"low":10.02,"amount":16290495.110404,"amplitude":0.045933,"askPrice":11.49,"askSize":100,"bidPrice":10.3,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.81541,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769092200000},"marketStatusCode":1,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":10.44,"preHourTrading":{"tag":"盘前","latestPrice":10.74,"preClose":10.44,"latestTime":"08:02 EST","volume":4,"amount":42.96,"timestamp":1769086976104,"change":0.3,"changeRate":0.028736,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10.57,"preClose":10.44,"latestTime":"19:51 EST","volume":18227,"amount":190420.5746,"timestamp":1769043115930,"change":0.13,"changeRate":0.012452,"amplitude":0.012452},"volumeRatio":1.193034469420588,"impliedVol":0.9862,"impliedVolPercentile":0.752},"requestUrl":"/m/hq/s/SPRY","defaultTab":"news","newsList":[{"id":"2603683635","title":"Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603683635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603683635?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:45","pubTimestamp":1768229110,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时45分,Ars Pharmaceuticals, Inc.股票出现波动,股价大幅下挫5.24%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.00%。其相关个股中,Cdt Equity Inc C/Wts 22/09/2028、Day One Biopharmaceuticals, Inc.、Forte Biosciences, Inc.涨幅较大,Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃,换手率分别为538.92%、111.61%、48.15%,振幅较大的相关个股有Pyxis Oncology, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Geovax Labs, Inc.,振幅分别为26.42%、25.56%、24.64%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222451097a17707&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222451097a17707&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1128364104","title":"ARS Pharmaceuticals将获400万美元监管里程碑付款,并有望获得高达8000万美元销售里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1128364104","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128364104?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:04","pubTimestamp":1767013484,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals(纳斯达克代码:SPRY)近日宣布,公司将获得一笔400万美元的监管里程碑付款。此外,根据相关协议条款,该公司还有资格获得最高达8000万美元的销售里程碑款项。这一进展标志着公司在商业化进程中迈出重要一步,也为未来业绩增长提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1199872730","title":"Neffy®(肾上腺素鼻喷雾剂)在华获批,成为首个且唯一可用于社区治疗的过敏反应(严重过敏)急救产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1199872730","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199872730?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:03","pubTimestamp":1767013385,"startTime":"0","endTime":"0","summary":"肾上腺素鼻喷雾剂Neffy®已正式获得中国监管部门的批准,该产品是首个且目前唯一获批用于社区场景、治疗过敏反应(严重过敏)的肾上腺素制剂。这一批准为患者提供了更为便捷和及时的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1133887171","title":"异动解读 | ARS制药季度业绩亮眼,股价盘前飙升7.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133887171","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133887171?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:38","pubTimestamp":1762778319,"startTime":"0","endTime":"0","summary":"周一盘前,ARS制药(股票代码:SPRY)股价大幅上涨7.34%,引起投资者广泛关注。\n\n这波涨势似乎源于公司刚刚发布的2025年第三季度财务报告。ARS制药在盘前公布了其最新季度业绩以及旗下产品Neffy®的最新进展,这份报告显然给市场带来了积极信号。\n\n尽管具体财务数据尚未完全披露,但投资者对这份报告反应热烈,推动股价在开盘前显著上涨。分析人士认为,这可能意味着公司的业绩超出市场预期,特别是Neffy®产品线的表现可能相当出色。随着交易日的开始,我们预计会看到更多关于ARS制药财报的详细分析和市场反应。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SPRY"],"gpt_icon":0},{"id":"1112333909","title":"ARS Pharmaceuticals公布2025年第三季度财务结果及Neffy®的亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=1112333909","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112333909?lang=zh_cn&edition=full","pubTime":"2025-11-10 19:02","pubTimestamp":1762772540,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals公布2025年第三季度财务结果及Neffy®的亮点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2581317590","title":"Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581317590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581317590?lang=zh_cn&edition=full","pubTime":"2025-11-06 03:43","pubTimestamp":1762371834,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日03时43分,Ars Pharmaceuticals, Inc.股票出现波动,股价快速拉升5.05%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.37%。其相关个股中,Pasithea Therapeutics Corp C/Wts 12/08/2026 、Sonnet Biotherapeutics Holdings, Inc.、Enveric Biosciences, Inc.涨幅较大,Lunai Bioworks Inc.、Immuron Limited、Metavia Inc.较为活跃,换手率分别为628.82%、88.40%、79.44%,振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Ethzilla Corporation C/Wts 06/11/2025、Lunai Bioworks Inc.,振幅分别为84.66%、75.37%、74.26%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106034355a48b58d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106034355a48b58d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1108658851","title":"ARS Pharma推出GET Neffy®以改善重度过敏反应患者对Neffy(肾上腺素鼻喷雾剂)的获取","url":"https://stock-news.laohu8.com/highlight/detail?id=1108658851","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108658851?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:01","pubTimestamp":1762261310,"startTime":"0","endTime":"0","summary":"ARS Pharma推出GET Neffy®,旨在为重度过敏反应患者改善对Neffy(肾上腺素鼻喷雾剂)的获取。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2578350371","title":"Ars Pharmaceuticals, Inc.盘中异动 临近收盘快速下跌5.08%报9.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578350371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578350371?lang=zh_cn&edition=full","pubTime":"2025-10-25 03:32","pubTimestamp":1761334366,"startTime":"0","endTime":"0","summary":"北京时间2025年10月25日03时32分,Ars Pharmaceuticals, Inc.股票出现异动,股价大幅跳水5.08%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.19%。其相关个股中,Inhibrx Biosciences, Inc.、Genenta Science Spa、Neuphoria Therapeutics Inc.涨幅较大,Neuphoria Therapeutics Inc.、Theriva Biologics, Inc.、Qualigen Therapeutics, Inc.较为活跃,换手率分别为3473.15%、2881.41%、2487.19%,振幅较大的相关个股有Theriva Biologics, Inc.、Genenta Science Spa、Nls Pharmaceutics Ltd C/Wts 02/02/2026,振幅分别为134.04%、133.75%、84.64%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025033246a6cc8e82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025033246a6cc8e82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2574772432","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574772432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574772432?lang=zh_cn&edition=full","pubTime":"2025-10-10 23:03","pubTimestamp":1760108595,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日23时03分,Ars Pharmaceuticals, Inc.股票出现异动,股价快速下挫5.01%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.73%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510102303159726ba39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510102303159726ba39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1170206591","title":"ARS Pharmaceuticals就Neffy®(肾上腺素鼻喷剂)相关专利获得欧洲专利局有利决定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170206591","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170206591?lang=zh_cn&edition=full","pubTime":"2025-10-08 20:04","pubTimestamp":1759925054,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals就其Neffy®(肾上腺素鼻喷剂)相关专利获得了欧洲专利局的有利决定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2572837839","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.45%报10.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572837839","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572837839?lang=zh_cn&edition=full","pubTime":"2025-09-30 21:33","pubTimestamp":1759239239,"startTime":"0","endTime":"0","summary":"北京时间2025年09月30日21时33分,Ars Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.45%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.28%。其相关个股中,Scisparc Ltd.、Anaptysbio, Inc.、Nanobiotix涨幅较大,Scisparc Ltd.、Qualigen Therapeutics, Inc.、Nls Pharmaceutics Ltd.较为活跃,换手率分别为898.49%、248.26%、247.74%,振幅较大的相关个股有Scisparc Ltd.、Silexion Therapeutics Corp、Barinthus Biotherapeutics Plc,振幅分别为19.51%、14.16%、11.49%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930213359971a6979&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930213359971a6979&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1146721721","title":"ARS Pharmaceuticals获得高达2.5亿美元贷款额度,与Ra Capital Management和Omers Life Sciences合作加速Neffy®在美国的商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1146721721","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146721721?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:06","pubTimestamp":1759176388,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals获得高达2.5亿美元贷款额度,与Ra Capital Management和Omers Life Sciences合作加速Neffy®在美国的商业化","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1132385495","title":"Neffy®(肾上腺素鼻喷剂)在日本获批,成为首个且唯一的无针头过敏反应(过敏性休克)紧急治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1132385495","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132385495?lang=zh_cn&edition=full","pubTime":"2025-09-19 20:01","pubTimestamp":1758283315,"startTime":"0","endTime":"0","summary":"Neffy®(肾上腺素鼻喷剂)在日本获批,成为首个且唯一的无针头过敏反应(过敏性休克)紧急治疗药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2568452409","title":"Ars Pharmaceuticals, Inc.盘中异动 临近收盘急速下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568452409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568452409?lang=zh_cn&edition=full","pubTime":"2025-09-17 03:41","pubTimestamp":1758051693,"startTime":"0","endTime":"0","summary":"北京时间2025年09月17日03时41分,Ars Pharmaceuticals, Inc.股票出现异动,股价快速下挫5.02%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。其相关个股中,Kalaris Therapeutics, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026、冠科美博涨幅较大,Aptevo Therapeutics Inc.、Adaptimmune Therapeutics Plc、Silo Pharma, Inc.较为活跃,换手率分别为3424.63%、174.64%、119.10%,振幅较大的相关个股有Aptevo Therapeutics Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026、Jasper Therapeutics Inc C/Wts 24/09/2026 ,振幅分别为89.58%、76.00%、44.27%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917034135a4ca1843&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917034135a4ca1843&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"1162831286","title":"异动解读 | ARS制药业绩报告后股价盘中大跌5.46%,尽管收入超预期但亏损仍然严重","url":"https://stock-news.laohu8.com/highlight/detail?id=1162831286","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162831286?lang=zh_cn&edition=full","pubTime":"2025-08-13 21:35","pubTimestamp":1755092142,"startTime":"0","endTime":"0","summary":"ARS制药今日盘中大跌5.46%,主要受到其最新季度财报的影响。尽管公司收入超出预期,但仍然面临严重亏损,引发了投资者对其财务状况的担忧。根据公司发布的财报显示,截至6月30日的季度中,ARS制药调整后每股亏损0.46美元,略好于分析师预期的0.47美元亏损。值得注意的是,尽管今日股价出现大幅下跌,ARS制药的股价今年迄今为止仍上涨了57.9%。这表明尽管短期内面临挑战,但市场对公司的长期发展前景仍持积极看法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SPRY"],"gpt_icon":0},{"id":"2558661690","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘快速下跌5.00%报16.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558661690","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558661690?lang=zh_cn&edition=full","pubTime":"2025-08-11 23:24","pubTimestamp":1754925885,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日23时24分,Ars Pharmaceuticals, Inc.股票出现异动,股价急速下挫5.00%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.30%。其相关个股中,Equillium, Inc.、Entero Therapeutics Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大,Entero Therapeutics Inc.、Equillium, Inc.、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为5577.18%、493.01%、169.67%,振幅较大的相关个股有Equillium, Inc.、Entero Therapeutics Inc.、Jyong Biotech Ltd.,振幅分别为84.05%、74.27%、62.69%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811232445a6dfe09f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811232445a6dfe09f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2517461243","title":"ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖,给予跑赢大盘评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461243","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517461243?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖,给予跑赢大盘评级, 目标价30.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SPRY"],"gpt_icon":0},{"id":"2517398688","title":"Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.01%报10.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517398688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517398688?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:18","pubTimestamp":1741119485,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时18分,Ars Pharmaceuticals, Inc.股票出现波动,股价大幅上涨5.01%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.07%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041805abe85197&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041805abe85197&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2514385185","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.57%报10.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385185","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385185?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666704,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分,Ars Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.57%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.06%。其相关个股中,Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Quoin Pharmaceuticals Ltd涨幅较大,Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃,换手率分别为405.81%、90.91%、50.39%,振幅较大的相关个股有Pds Biotechnology Corporation、天演药业、Syros Pharmaceuticals, Inc.,振幅分别为11.69%、10.10%、10.09%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223144abdf6e9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223144abdf6e9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2513377332","title":"Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.16%报10.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513377332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513377332?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:31","pubTimestamp":1740411117,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时31分,Ars Pharmaceuticals, Inc.股票出现波动,股价急速跳水5.16%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.21%。其相关个股中,Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为205.96%、86.70%、27.91%,振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ,振幅分别为137.23%、55.69%、53.34%。Ars Pharmaceuticals, Inc.公司简介:ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233158a25222ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233158a25222ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":-0.1145},{"period":"1month","weight":-0.081},{"period":"3month","weight":0.0819},{"period":"6month","weight":-0.4158},{"period":"1year","weight":-0.2255},{"period":"ytd","weight":-0.1039}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ARS Pharmaceuticals, Inc.于2016年1月4日根据特拉华州法律成立。该公司是一家生物制药公司,专注于开发新型、可能是一流的候选产品,neffy用于I型过敏反应的紧急治疗,包括过敏反应。neffy是一种肾上腺素的专有组合物,具有一种名为Intravail的创新吸收增强剂,允许neffy以小剂量、易于携带、易于使用、快速给药和可靠的鼻喷雾剂提供注射般的肾上腺素吸收。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.042217},{"month":2,"riseRate":0.6,"avgChangeRate":0.08605},{"month":3,"riseRate":0.4,"avgChangeRate":-0.024933},{"month":4,"riseRate":0.2,"avgChangeRate":-0.083829},{"month":5,"riseRate":0.8,"avgChangeRate":0.021109},{"month":6,"riseRate":0.6,"avgChangeRate":0.093442},{"month":7,"riseRate":0.8,"avgChangeRate":0.11695},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080641},{"month":9,"riseRate":0.2,"avgChangeRate":-0.212128},{"month":10,"riseRate":0.4,"avgChangeRate":-0.021216},{"month":11,"riseRate":0.4,"avgChangeRate":0.043601},{"month":12,"riseRate":0.6,"avgChangeRate":0.080317}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ARS PHARMACEUTICALS INC(SPRY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ARS PHARMACEUTICALS INC(SPRY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}